Delivery Order SPE2DB20D2014-SPE2DB24FC73U

Award Date 8/12/24
Potential Completion Date 8/13/24
Potential Value $15K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 ml) to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor that plays a critical role in supplying medical products to federal government agencies. The contract, valued at $15,773.30, is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 and...
This federal contract award is for the delivery of GARDASIL 9 SYRINGE 0.5ML to the U.S. government. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract has a ceiling value of $14,162.95 and is a Firm Fixed Price Delivery Order. It does not have a set-aside designation. This contract award is likely part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the...
This federal contract award is for the delivery of GARDASIL 9 SYRINGE 0.5ML to the Defense Logistics Agency (DLA), a defense agency. The $10,009.41 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on February 7, 2025, with a final completion date of February 10, 2025. The contract is not designated as a set-aside. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award is for the delivery of GARDASIL 9 SYRINGE 0.5ML medical products to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a firm fixed price of $5,111.46 and an ultimate completion date of December 16, 2024. It is a delivery order contract and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a...
The federal contract award is for the delivery of GARDASIL 9 syringes, a vaccine product, to the Defense Logistics Agency (DLA), a defense agency. The $34,961.38 firm fixed-price delivery order contract with Amerisourcebergen Drug Corp, a major pharmaceutical distributor, has a completion date of June 18, 2025. This delivery order is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which provides comprehensive...
This federal contract award is for the delivery of GARDASIL 9 SYRINGE 0.5ML to the Defense Logistics Agency (DLA). The $10,556.42 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a completion date of June 22, 2023 and was awarded on June 21, 2023. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award is for the delivery of GARDASIL 9 SYRINGE 0.5ML to the Defense Logistics Agency (DLA), a Defense agency. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for a total ceiling value of $13,363.82. The contract is a Delivery Order with a Firm Fixed Price pricing type, with an ultimate completion date of April 19, 2023. The contract is not designated with a set-aside. AmerisourceBergen Drug Corp...
This federal contract award is for the delivery of GARDASIL 9 SYRINGE 0.5ML to the Defense Logistics Agency (DLA). The $23,926.46 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a completion date of September 12, 2024 and was awarded on September 11, 2024. This award is a child contract under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen...
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 mL) to the Defense Logistics Agency (DLA). The award, valued at $3,898.37, was made on February 28, 2025 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, with a period of performance through March 3, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which provides a...
This federal contract award, valued at $7,563.71, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp for the delivery of GARDASIL 9 SYRINGE 0.5ML. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of August 7, 2024. Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was awarded this contract to supply the DLA with the specified vaccine. This contract is part of a larger Indefinite Delivery Contract (IDC) with the DLA...
  • SPE2DB20D2014
    Indefinite Delivery Contract
  • SPE2DB20D2014-SPE2DB24FC73U
    Delivery Order

This federal contract award is for the delivery of GARDASIL 9 SYRINGE 0.5ML pharmaceutical products to the Defense Logistics Agency (DLA). The contract, valued at $15,049.24, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. As a Delivery Order contract, this represents an individual order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued up to $999,999,999 through December 2025. The contract is for a Firm Fixed Price and does not have any set-aside designation. This contract supports the DLA's role in providing essential medical commodities, including vaccines and other pharmaceutical products, to military treatment facilities and other federal healthcare providers.

Generated 11/11/24, 9:28 AM